5-year Impact Research Articles

Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective.

Gliflozins have historically been indicated for type 2 diabetes in France. However, their efficacy has recently been demonstrated in heart failure and chronic kidney disease (CKD), with positive recommendations by Haute Autorité de Santé for gliflozin therapies in these indications. The study objective was to investigate the 5-year budget impact associated with the introduction of gliflozins in addition to standard therapy in people with CKD and elevated albuminuria, regardless of diabetes status, from the perspective of the French healthcare system. A budget impact model was developed to estimate the 5-year implications of incorporating gliflozins in the treatment of patients withCKD in France, using efficacy data from the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial. Direct medical costs associated with drug acquisition and management, treatment-related adverse events, dialysis and kidney transplantation, and adverse clinical outcomes were considered. Market share forecasts were estimated from historical data and expert opinions. Event rates were derived from trial data, while cost data were sourced from published estimates. The introduction of gliflozins was estimated to be cost saving compared to the no gliflozins scenario, with an expected cumulative 5-year budget impact of -€650 million, driven by slowed disease progression in patients treated with gliflozins, with fewer patients cumulatively progressing to end-stage kidney disease (84,526 vs. 92,062). This, in addition to fewer hospitalisations for heart failure and deaths from any cause, led to substantial medical care cost offsets (kidney-related: -€894 million; hospitalisation for heart failure: -€14.3 million; end-of-life care: -€17.3 million) to the additional drug acquisition (€273 million) and treatment-related adverse events costs (€2.98 million). In concert with early diagnosis and proactive management of CKD, the expansion of the gliflozin indications into the French CKD population presents the opportunity to reduce the substantial burden associated with cardio-renal complications which outweighs the additional cost of the new treatment. INFOGRAPHIC.

Bibliometric analysis of the top 100 cited articles in breast radiology.

Bibliometrics analysis is a widely used approach that enables influential research within specific fields to be identifiedTo identify the 100 most-cited articles in breast radiology and analyse the trend in breast imaging research. A systematic search was conducted using the Thomson Rheuters Web of Science database. The results were ranked according to citation count and screened to create a single database. Data including first author, year of publication, journal, country of origin, primary institution, number of citations and average number of citations per year were extracted, as well as the impact factor and the 5-year impact factor of journals publishing the articles. The systematic search yielded a total of 114,426 articles, after filters were applied to include papers that were available in English only. Citations for the 100 most-cited articles ranged from 515 to 3660. Half of the articles on the list were published between 2001 and 2010. Radiology has the most number of publications (n = 17), followed by JAMA-Journal of The American Medical Association (n = 9). CA-A Cancer Journal For Clinicians had the highest impact factor of 286.13. Mammogram (n = 49) was the most commonly studied modality, followed by Magnetic Resonance (n = 26). The most common topic of publication was diagnosis (n = 83). This research serves as a guide to the most influential articles on the topic of breast radiology.

The health and budget impact of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in The Netherlands

ObjectivesType-2 Diabetes mellitus (T2DM) increases both the patient risk of cardiovascular disease (CVD) and renal outcomes, such as chronic kidney disease (CKD). Recent clinical trials of the glucose-lowering drug-class of sodium-glucose co-transporter-2 inhibitors (SGLT2is) have shown benefits in preventing CVD events and progression of CKD, leading to an update of the Dutch T2DM treatment guideline for patients at risk. The aim of this study is to assess the health and economic impact of the guideline-recommended utilization of SGLT2is in the Netherlands.MethodsThe patient population at risk was determined by multiplying Dutch T2DM prevalence rates with the total numbers of inhabitants of the Netherlands in 2020. Subsequently, two analyses, comparing a treatment setting before and after implementation of the new guideline for SGLT2is, were conducted. Clinical and adverse event rates in both settings as well as direct healthcare costs were sourced from the literature. Total costs were calculated by multiplying disease prevalence, event rates and costs associated to outcomes. One-time disutilities per event were included to estimate the health impact. The potential health and economic impact of implementing the updated guideline was calculated.ResultsUsing a 5-year time horizon, the guideline-suggested utilization of SGLT2is resulted in a health impact equal to 4835 quality adjusted life years gained (0.0031 per patient per year) and €461 million cost-savings. The costs of treatment with SGLT2is were €813 million. Hence the net budget impact was €352 million for the total Dutch T2DM population, which translated to €0,57 per patient per day.ConclusionSGLT2is offer an option to reduce the number of CVD and CKD related events and associated healthcare costs and health losses in the Netherlands. Further research is needed to include the benefits of improved T2DM management options from a broader societal perspective.HighlightsThe glucose-lowering drug-class of sodium-glucose co-transporter-2 inhibitors (SGLT2is) has shown benefits in preventing cardiovascular events and progression of kidney disease in patients with type-2 diabetes leading to a revision of the respective Dutch treatment guideline.The 5-year budget impact of the adoption of SGLT2is in the new treatment guideline was equal to €352 million or €0.57 per patient per day, with a total of 4385 quality adjusted life years gained.The introduction of SGLT2is for Dutch type-2 diabetes patients has the potential to substantially reduce the number of cardiovascular as well as renal disease events and related healthcare costs while also delivering a health benefit.

Accuracy of data in abstracts of veterinary ophthalmology research articles published in peer-reviewed journals.

Assess the accuracy of abstracts in published veterinary ophthalmology articles. Abstracts and contents of 204 original research articles in veterinary ophthalmology published in seven peer-reviewed journals between 2016-2020 were reviewed. Abstracts were considered inconsistent if they contained data that were either missing from or inconsistent with corresponding data in the article's body. Each abstract was graded between 0 (inaccurate) to 3 (accurate), and each inconsistency was subjectively classified as minor or major. The influence of selected variables was assessed: journal, impact factor, year of publication, number of words in abstract, study type (prospective/retrospective), and characteristics of the corresponding author [institution (academia/private practice), country of domicile (native/non-native English), number of publications]. Most abstracts were accurate, with 1%, 4%, 9% and 86% receiving a score of 0, 1, 2 and 3, respectively. When detected, most inconsistencies were considered minor (77%). Although not statistically significant (p≥ .130), the proportion of articles with a perfect score (=3) was higher in prospective (88%) vs. retrospective (81%) studies, academia (88%) vs. private practice (78%), and studies from corresponding authors domiciled in English (89%) vs. non-English (83%) speaking countries. A significant but very weak (r= -0.15 to -0.19; p≤ .034) negative correlation was found between accuracy score and number of words, as well as 1-year and 5-year impact factors. Although relatively uncommon, data in abstracts that are inconsistent or missing from the article's body do occur in veterinary ophthalmology articles, and could adversely influence a reader's interpretation of study findings.

Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options.

A scaled-up treatment cascade with direct-acting antiviral (DAA) therapy is necessary to achieve global WHO targets for hepatitis C virus (HCV) elimination in Malaysia. Recently, limited access to sofosbuvir/daclatasvir (SOF/DAC) is available through compulsory licensing, with access to sofosbuvir/velpatasvir (SOF/VEL) expected through voluntary licensing due to recent agreements. SOF/VEL has superior clinical outcomes but has higher drug acquisition costs compared to SOF/DAC. A stratified treatment cascade might be the most cost-efficient approach for Malaysia whereby all HCV patients are treated with SOF/DAC except for patients with cirrhosis who are treated with SOF/VEL. This study aimed to conduct a 5-year budget impact analysis of the proposed stratified treatment cascade for HCV treatment in Malaysia. A disease progression model that was developed based on model-predicted HCV epidemiology data was used for the analysis, where all HCV patients in scenario A were treated with SOF/DAC for all disease stages while in scenario B, SOF/DAC was used only for non-cirrhotic patients and SOF/VEL was used for the cirrhotic patients. Healthcare costs associated with DAA therapy and disease stage monitoring were included to estimate the downstream cost implications. The stratified treatment cascade with 109 in Scenario B was found to be cost-saving compared to Scenario A. The cumulative savings for the stratified treatment cascade was USD 1.4 million over 5 years. A stratified treatment cascade with SOF/VEL was expected to be cost-saving and can result in a budget impact reduction in overall healthcare expenditure in Malaysia.

The Correlation between Altmetric Attention Score and Traditional Bibliometrics in Top Nursing Journal Articles

Background. Altmetric Attention Score (AAS) is a quantitative measurement of the online impact of research and has a potential correlation with traditional bibliometrics. However, the correlation for nursing journal articles is still unknown. The objective of the study was to analyze the correlation between AAS and traditional bibliometrics in the top nursing journal articles. Materials and Methods. Articles published in top nursing journals (the journals with the top 20 5-year impact factors) from 2010 to 2019 were included. The correlations between AAS and citations, AAS and Relative Citation Ratio (RCR) score, AAS and Category Normalized Citation Impact (CNCI) value, and AAS and impact factors were analyzed. Statistical analyses were performed using Stata 25.0 software. Results. A total of 15,212 journal articles were included in the study. Very weak correlations were found between AASs and citations [0.124 (95% CI, 0.108–0.14)], AASs and RCRs [0.26 (95% CI, 0.244–0.275)], and AASs and CNCIs [0.207 (95% CI, 0.192–0.223)]. The weak correlations were also found between AASs and impact factors in several journals. The weak correlations between AASs and citations, AASs and CNCIs, and AASs and RCRs were also found for most journals based on subgroup analysis. Conclusions. There is very weak correlations between AASs and traditional bibliometrics in top nursing journal articles. More studies should be conducted to assess how AAS influence bibliometrics, and how they can help manage nursing journal articles and research.

How publication timelines effect the impact metrics: studying the influence of submission to first decision and submission to acceptance on impact factor and 5-year impact factor of journals

Purpose The purpose of the study is to analyze the impact of the Publication Timeline, i.e. Submission to First Decision and Submission to Acceptance on Journal Metrics, i.e. Impact Factor (IF) and 5-year IF. Design/methodology/approach Data related to the IF and 5-year IF were retrieved from Clarivate Analytics’ Journal Citation Report 2020. The Publication Timeline of each journal was ascertained through their respective websites. To attain the model fit summary, an analysis of variance (ANOVA) test was performed. Regression analysis was also performed on the models using SPSS 21 software to ascertain the nature and degree of impact the Publication Timeline (Submission to First Decision and Submission to Acceptance) has on Journal Metrics (IF and 5-year IF). Findings Submission to First Decision has a significant inverse relationship with both the IF and 5-year IF, whereas Submission to Acceptance has a significant direct relation with 5-year IF and an inverse but insignificant relationship with IF. Research limitations/implications Journals published by Springer Nature and of multidisciplinary nature have been considered for the study. Only those journals were selected that provided the information regarding the Publication Timeline, whereas those which did not provide the same, were excluded. However, new insights can be revealed if the journals published by different publishers and belonging to one particular discipline are studied. Practical implications The study helps to ascertain the impact of the Publication Timeline on the Impact Metrics of the journals. It can help the authors select the journals as their publishing venues considering the Publication Timeline. Publishers can also be benefitted from the findings of this study since improvisations and modifications in their Publication Timelines can positively influence the impact metrics of their respective journals. Originality/value The study attempts to measure the impact of the Publication Timeline on Journal Metrics using cross-sectional secondary data, by performing regression analysis. Though various studies have examined the influence of the Publication Timeline on the IF using correlation analysis, to the best of the authors’ knowledge, this study is the first of its kind to use regression analysis to check the relation, as well as the degree of impact the Publication Timeline, has on Journal Metrics.

Acute Kidney Injury in Patients with Leukaemia Submitted to Allogeneic Hematopoietic Stem Cell Transplant – KDIGO Classification with Creatinine and Urinary Output Criteria: Cohort Analysis

Background: Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) is often complicated by Acute Kidney Injury (AKI) and has been increasingly used in patients with leukaemia. Studies on this subject include patients with several haematological diseases and use only Serum Creatinine (SCr) to define AKI. We aimed to evaluate incidence, risk factors and 5-year prognostic impact of AKI in patients with leukaemia submitted to allo-HSCT by SCr and Urinary Output (UO). Methods: We conducted a single-centre retrospective cohort study. AKI was defined according to KDIGO classification. We used survival analysis methods considering competing events - the Fine and Gray method - to identify AKI risk factors and assess the impact of AKI on disease-free survival. Additive Cox proportional hazards regression models were applied to analyse time until death from all causes. Stepwise selection regression methods were used to create the final multivariable model. Results: We included 164 patients. The cumulative incidence of AKI was 63.4% 100 days post-HSCT. On the first day of AKI, 76.9% presented SCr criteria, 15.4% presented UO criteria and 7.7% presented both criteria. The highest stage of AKI was 1 in 61.8%, 2 in 21.6% and 3 in 16.7%. Variables independently associated with AKI: HCT-CI >2 (HR:1.88,95%CI:1.13- 3.11;p=0.015), radiotherapy in the past (HR:2.07,95%CI:2.07- 1.06;p=0.034), LDH at hospital admission (HR:1.51,95%CI:1.03- 2.21;p=0.035), shock (HR:1.57,95%CI:1.02-2.39;p=0.039), and sepsis (HR:3.36,95%CI:1.22-9.24;p=0.019). Severe AKI was independently associated with lower overall survival along the first 5 years (HR:1.76,95%CI:1.03-3.00;p=0.037). Conclusion: AKI in leukaemia patients submitted to allo-HSCT had a cumulative incidence of 63.4% and more than 15% of these patients presented only with UO reduction on the day of AKI onset. Two thirds of the patients evolved with AKI stage 2 or 3. Sepsis, previous radiotherapy treatments at any time before HSCT, HCT-CI scoring higher than 2 points, shock and higher LDH levels increased the risk of developing AKI. Severe AKI was associated to lower overall survival throughout the first five years after allo-HSCT. To our knowledge, this is the first study considering both SCr and UO for AKI patients with Leukaemia submitted to allogeneic Hematopoietic Stem Cell Transplant.

H-Index, Journal Citation Indicator, and Other Impact Factors in Neurosurgical Publications: Is There a Cost Factor That Determines the Quality?

There has been an increase in number of Neurosurgical publications, including open access (OA), in recent years. We aimed to compare journals' performance and the relationship to submission fees incurred in publication. We identified 53 journals issuing neurosurgery-related work. Quantitative analysis from various search engines involved obtaining h-index, Journal Citation Indicator (JCI), and other metrics such as Immediacy Index and 5-year impact factor utilising Journal Citation Reports. OA fees and individual subscription fees were collected. Correlations were produced using Spearman rho (ρ) (P < 0.05). Median h-index for 53 journals was 54 (range: 0-292), with JCI median reported as 0.785 (range: 0-2.45). Median Immediacy Index was 0.797 (range: 0-4.076), and median for 5-year impact factor was 2.76 (range: 0-12.704). There was a very strong positive correlation between JCI and Immediacy Index, JCI and 5-year impact factor, and 5-year impact factor and Immediacy Index (ρ > 0.7, P < 0.05). It is unclear whether there was any correlation between the indices and the OA costs and subscription costs for personal usage (P > 0.05). Larger costs incurred for OA fees and subscription costs for personal use do not clearly reflect on the journals' performance, as quantified by using various indices. There appears to be a strong association with performance across the journals' metrics. It would be beneficial to include learning about bibliometric indices' impact for research publications in medical education training to maximize the quality of the scientific work produced and increase the visibility of the information produced. The potential full movement to exclusively OA journals would create a significant barrier for junior researchers, small institutions, and full time-trainee physicians with limited funding available. This study suggests the need for a robust measurement of journals' output and the quality of the work produced.

Characterization of the Conversion of Meeting Presentation to Publication From the 2016 and 2018 ISSVA Workshops

Objectives: Presentations at scientific conferences and subsequent publications play a critical role in a specialty’s advancement. Previous estimates suggest that about half of the content presented at conferences is not published. The objective of this study is to characterize the conversion from meeting presentations to publications from the 2016 and 2018 International Society for the Study of Vascular Anomalies (ISSVA) Workshops. Methods: The PubMed interface (MEDLINE) and Google Scholar were used to search for published works. Excluded presentations included keynotes, research letters, and education-related theses. Parameters reviewed included conversion rate, time to publication, senior author subspecialty, study design and level of evidence, journal name, and 5-year impact factor. Results: 40.43% of searched conference abstracts were published in peer-reviewed journals. The median publication time from presentation was 16 months (range −28.9 to 41.1). The most frequent specialties of 224 senior authors were: plastic surgery (21.4%), dermatology (20.0%), and radiology (10.7%). Authors published in 111 separate journals, where the majority of publications appeared in Pediatric Dermatology (5.8%). A majority of publications (51.3%) had a case series study design and were level 4 evidence. The median 5-year impact factor was 3.49. Conclusions: From the 2016 and 2018 ISSVA meetings reviewed, less than half of presentations were converted to publications. Studies were published in a wide range of journals, in alignment with specialty. A significant portion of vascular anomalies research at ISSVA that may have the potential to improve patient care does not reach a wider audience.

Effectiveness and cost-effectiveness of referral to a commercial open group behavioural weight management programme in adults with overweight and obesity: 5-year follow-up of the WRAP randomised controlled trial

There is evidence that commercially available behavioural weight management programmes can lead to short-term weight loss and reductions in glycaemia. Here, we aimed to provide the 5-year impact and cost-effectiveness of these interventions compared with a brief intervention. WRAP was a non-blinded, parallel-group randomised controlled trial (RCT). We recruited from primary care practices in England and randomly assigned participants to one of three interventions (brief intervention, 12-week open-group behavioural programme [WW, formerly Weight Watchers], or a 52-week open-group WW behavioural programme) in an uneven (2:5:5) allocation. Participants were followed up 5 years after randomisation using data from measurement visits at primary care practices or a research centre, review of primary care electronic medical notes, and self-report questionnaires. The primary outcome was change in weight at 5 years follow-up, assessed using analysis of covariance. We also estimated cost-effectiveness of the intervention. This study is registered at Current Controlled Trials, ISRCTN64986150. Between Oct 18, 2012, and Feb 10, 2014, we recruited 1269 eligible participants (two participants were randomly assigned but not eligible and therefore excluded) and 1040 (82%) consented to be approached about additional follow-up and to have their medical notes reviewed at 5 years. The primary outcome (weight) was ascertained for 871 (69%) of 1267 eligible participants. Mean duration of follow-up was 5·1 (SD 0·3) years. Mean weight change from baseline to 5 years was -0·46 (SD 8·31) kg in the brief intervention group, -1·95 (9·55) kg in the 12-week programme group, and -2·67 (9·81) kg in the 52-week programme. The adjusted difference in weight change was -1·76 (95% CI -3·68 to 0·17) kg between the 52-week programme and the brief intervention; -0·80 (-2·13 to 0·54) kg between the 52-week and the 12-week programme; and -0·96 (-2·90 to 0·97) kg between the 12-week programme and the brief intervention. During the trial, the 12-week programme incurred the lowest cost and produced the highest quality-adjusted life-years (QALY). Simulations beyond 5 years suggested that the 52-week programme would deliver the highest QALYs at the lowest cost and would be the most cost-effective. No participants reported adverse events related to the intervention. Although the difference in weight change between groups was not statistically significant, some weight loss was maintained at 5 years after an open-group behavioural weight management programme. Health economic modelling suggests that this could have important implications to reduce the incidence of weight-related disease and these interventions might be cost-saving. The UK National Institute for Health and Care Research Programme Grants for Applied Research and the Medical Research Council.

Editorial Outstanding Associate Editors and Top Reviewers

The IEEE Transactions on Antennas and Propagation is one of the most influential publications of IEEE. Its scientific contributions attract a lot of interest and are among the most downloaded across all IEEE publications. In 2021, the IEEE Transactions on Antennas and Propagation ranked third out of 389 publications available on IEEE Xplore for total number of downloads. The IEEE Transactions on Antennas and Propagation ranks second for total number of downloads out of all IEEE publications, when open access journals are excluded. In addition, the bibliometric measures released by Clarivate for year 2021 indicate that the journal performance has set a new record in its history, with an impact factor of 4.824, a 5-year impact factor that reached 5.005, an eigenfactor score of 0.041, and article influence score of 1.048.

Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease.

ObjectiveWe aimed to estimate the cost-effectiveness, burden of disease and budget impact of inclisiran added to standard-of-care lipid-lowering therapy in the real-world secondary cardiovascular prevention population in Switzerland.MethodsAn open-cohort Markov model captured event risks by sex, age and low-density lipoprotein cholesterol based on epidemiological and real-world data. Low-density lipoprotein cholesterol reduction with add-on inclisiran was based on trial results and translated to meta-analysis-based relative risks of cardiovascular events. Unit costs for 2018 were based on publicly available sources, adopting a Swiss healthcare system perspective. Price assumptions of Swiss francs (CHF) 500 and CHF 3,000 per dose of inclisiran were evaluated, combined with uptake assumptions for burden of disease and budget impact. The assessment of cost-effectiveness used a discount rate of 3% per year. We performed deterministic and probabilistic sensitivity analyses, and extensive scenario analyses.ResultsPatients treated with inclisiran gained a 0.291 qualityadjusted life-year at an incremental cost per QALY gained of CHF 21,107/228,040 (life-long time horizon, discount rate 3%) under the lower/higher price. Inclisiran prevented 1025 cardiovascular deaths, 3425 acute coronary syndrome episodes, and 1961 strokes in 48,823 patients ever treated during 10 years; the 5-year budget impact was CHF 49.3/573.4 million under the lower/higher price. Estimates were sensitive to calibration targets and treatment eligibility; burden of disease/budget impact results also to uptake. Limitations included uncertainties about model assumptions and the size and characteristics of the population modelled.ConclusionsInclisiran may be cost-effective at a willingness to pay of CHF 30,000 if priced at CHF 500; a threshold upwards of CHF 250,000 will be required if priced at CHF 3000. Inclisiran could enable important reductions in cardiovascular burden particularly under broader eligibility with a budget impact range from moderate to high depending on price.Supplementary InformationThe online version contains supplementary material available at 10.1007/s40273-022-01152-8.

Hospital Cost Savings for Sequential COPD Patients Receiving Domiciliary Nasal High Flow Therapy.

PurposeTo estimate the 5-year budget impact to Aotearoa New Zealand (NZ) hospitals of domiciliary nasal high flow (NHF) therapy to patients with chronic obstructive pulmonary disease (COPD) who require long term oxygen therapy.MethodsHospital admission counts along with length of stay were obtained from hospital records of 200 COPD patients enrolled in a 12-month randomized clinical trial of NHF in Denmark, both over a 12-month baseline and then in the study period while on randomized treatment (control or NHF). NZ costings from similar COPD patients were estimated using data from Middlemore Hospital, Auckland and were applied to the Danish trial. The budget impact of NHF was estimated over the predicted 5-year lifetime of the device when used by patients sequentially.ResultsFifty-five of 100 patients in the NHF group and 44 of 100 patients in the control group were admitted to hospital with a respiratory diagnosis during the baseline year. They had 108 admissions in the treatment group vs 89 in the control group, with 632 vs 438 days in hospital, and modeled annual costs of $9443 vs $6512 per patient, respectively. During the study period there were 38 vs 44 patients with 67 vs 80 admissions and 302 vs 526 days in hospital, at a modeled annual cost of $6961 vs $9565 per patient respectively. Taking into account capital expenditure and running costs, this resulted in cost savings of $5535 per patient-year (95% CI, -$36 to -$11,034). With 90% usage over the estimated five-year lifetime of the NHF device, amortized capital costs of $594 per year and annual running costs of $662, we estimate a 5-year undiscounted cost saving per NHF device of $18,626 ($16,934 when discounted to net present value at 5% per annum). There would still be annual cost savings over a wide range of assumptions.ConclusionDomiciliary NHF therapy for patients with severe COPD has the potential to provide substantial hospital cost savings over the five-year lifetime of the NHF device.

The Kenevo microprocessor-controlled prosthetic knee compared with non-microprocessor-controlled knees in individuals older than 65 years in Sweden: A cost-effectiveness and budget-impact analysis.

Background:Growing evidence suggests that individuals with transfemoral amputation or knee disarticulation using a prosthesis equipped with a microprocessor-controlled knee (MPK) benefit from enhanced mobility and safety, including less falls. In elderly individuals, high mortality rates are assumed to reduce the expected useful life of MPKs, and this raises concerns regarding their economic effectiveness.Objective:To investigate the cost-effectiveness and budget impact of the Kenevo/MPK (Ottobock, Germany) compared with non–microprocessor-controlled knees (NMPKs) in people older than 65 years at the time of transfemoral amputation/knee disarticulation, from a Swedish payer’s perspective.Methods:A decision-analytic model was developed to conduct the economic analysis of the Kenevo/MPK. Model parameters were derived from Swedish databases and published literature. Univariate and probabilistic sensitivity analyses were performed to explore parameter uncertainty.Results:Compared with NMPKs, the Kenevo/MPK reduced the frequency of hospitalizations by 137 per 1,000 person years while the frequency of fatal falls was reduced by 19 per 1,000 person-years in the simulation. Over a 25-year time horizon, the incremental cost-effectiveness ratio was EUR11,369 per quality-adjusted life year. The probability of the MPK being cost-effective at a threshold of EUR40,000 per quality-adjusted life year was 99%. The 5-year budget impact model predicted an increase in payer expenditure of EUR1.76 million if all new patients received a Kenevo/MPK, and 50% of current NMPK users switched to the MPK.Conclusions:Results of the modeling suggest that the Kenevo/MPK is likely to be cost-effective for elderly individuals, primarily because of a reduction in falls.

Pharmacy practice research in Saudi Arabia; A bibliometrics analysis from (2000 to 2021)

BackgroundPharmacy is a growing profession in the Kingdom of Saudi Arabia which has experienced tremendous changes in the past 20 years. Pharmacy practice or clinical pharmacy have an attention ever since the emerging of PharmD programs throughout the Saudi universities. As a result, the number of affiliated faculty in the pharmacy practice departments has increased dramatically in the past 20 years and thus significant changes in research output were observed. ObjectivesThe main objective is to conduct a bibliometric analysis and evaluate the research output of pharmacy practice faculty in Saudi Universities from 2000 to 2021 MethodsA systematic search was conducted using Scopus database to explore the research output from pharmacy practice affiliated faculty from 2000 to 2021. The following search terms AFFILORG (“Pharmacy Practice Department” OR “Department of Pharmacy practice” OR “Clinical Pharmacy Department” OR “Department of Clinical Pharmacy” OR “Department of Pharmacy Services”) AND AFFILCOUNTRY (“Saudi Arabia” OR “KSA” OR “Kingdom of Saudi Arabia”) were used. Only original research papers were retrieved and analyzed using MS Excel (v16.0), MS Access (v16.0), Bibexcel (v2017), VOS viewer, and Biblioshiny. ResultsIn the past two decades, most publications with pharmacy practice departments affiliation were pharmacy practice research irrelevant (only 1075 out of 2809). King Saud University and King Abdulaziz University were the top performing institutes, and median of 5-year impact factor for journals was more than 3 for most of the top 10 institutes. 19% of the total retrieved articles were review publications were the rest majorly classified as cross-sectional studies. ConclusionThe research contribution of pharmacy practice departments in Saudi Arabia has been improving. Key recommendations are to promote more applied and interventional research, increase publications in top journals, and enhance national collaborations.

The cost-effectiveness of a resilience-based psychosocial intervention for HIV prevention among MSM in India.

MSM in India are at a high risk for HIV infection given psychosocial challenges, sexual orientation stress, and stigma. We examined the cost-effectiveness of a novel resilience-based psychosocial intervention for MSM in India. We parameterized a validated microsimulation model (CEPAC) with India-specific data and results from a randomized trial and examined two strategies for MSM: status quo HIV care ( SQ ), and a trial-based psychosocial intervention ( INT ) focused on building resilience to stress, improving mental health, and reducing condomless anal sex (CAS). We projected lifetime clinical and economic outcomes for MSM without HIV initially. Intervention effectiveness, defined as reduction in self-reported CAS, was estimated at 38%; cost was $49.37/participant. We used a willingness-to-pay threshold of US$2100 (2019 Indian per capita GDP) per year of life saved (YLS) to define cost-effectiveness. We also assessed the 5-year budget impact of offering this intervention to 20% of Indian MSM. Model projections showed the intervention would avert 2940 HIV infections among MSM over 10 years. Over a lifetime horizon, the intervention was cost-effective (ICER = $900/YLS). Results were most sensitive to intervention effectiveness and cost; the intervention remained cost-effective under plausible ranges of these parameters. Offering this intervention in the public sector would require an additional US$28 M over 5 years compared with SQ . A resilience-based psychosocial intervention integrated with HIV risk reduction counseling among MSM in India would reduce HIV infections and be cost-effective. Programs using this approach should be expanded as a part of comprehensive HIV prevention in India.

The Long-term (5-year) Impact of a Family Economic Empowerment Intervention on Adolescents Living with HIV in Uganda: Analysis of Longitudinal Data from a Cluster Randomized Controlled Trial from the Suubi+Adherence Study (2012-2018).

150/150 words.We examined the 5-year impact of an economic empowerment (EE) intervention on: adherence, viral suppression, sexual risk-taking intentions (primary); and physical health, educational and economic (secondary) outcomes among adolescents living with HIV in Uganda. The Suubi + Adherence study (2012-2018) randomized clinics to: (1) Control group, n = 19 clinics, n = 344 participants; (2) intervention group which received matched savings accounts, mentorship, financial management and, business development training, n = 20 clinics, n = 358 participants. Participants completed post-baseline assessments at 12-, 24-, 36-, and 48-months. No significant differences in viral load, sexual risk-intentions and physical health perception were observed. The intervention group had better adherence (at 24-months) (Contrast=-0.28; 95% CI: -0.55, -0.004), higher school enrolment (OR = 2.18; 95% CI:1.30, 3.66); reported savings OR = 2.03 (1.29, 3.18) and higher savings (Contrast = 0.40; 95% CI:0.10, 0.70) than controls at 48-months. The EE intervention was efficacious in improving adherence, school enrolment, and economic outcomes creating opportunities for improved overall health among adolescents living with HIV.

Publication Activity Analysis of Scientific Practical Journal “Intelligent Systems in Manufacturing”

The analysis of publication activity of the journal as at 2021. Since January 2019 journal “Intelligent Systems in Manufacturing” has been reorganized and today it has 2 sections for engineering sciences: “Instrumentation” and “Informatics”. Since that time, the journal has been publishing 14 articles per issue having 9 pages each on average. The editorial board consists of 22 scholars, among them 4 foreign scholars and 4 scholars from other regions of the Russian Federation. Blind peer view of articles is applied to enhance the quality of an article, peer views are published on the portal E-library, and the number of the rejected articles has increased due to low scientific merit up to 20 per cent. The journal site and the information of the journal in Russian Science Citation Index have been upgraded. Article content has been enhanced by means of complementary parallel headlines and information in English: article headline, authors, abstract, references, picture captures, and tables. Abstract and conclusion informative value are subjected to restricted requirements, requirements to references became as follows: at least 15 references to articles published during last 3 - 5 years including foreign ones. Publication activity of the journal in 2020 compared to 2018 has significantly increased according to majority of indicators: 2-year impact-factor for RSCI has become 1.5 times higher, a 2-year impact-factor for RSCI taking into account to citation of all references has also become 1.5 times higher: a 2-year impact factor for RSCI core has become 3 times higher. A 5-year impact factor for RSCI does not intensively respond to the changes happened during the last years, however, it is increasing. A 5-year-factor for RSCI core has the tendency to 1.5-time increasing. Percentage of a 2-year self-citation factor of the journal is not stable and exceeds 50 per cent. A 2-year self-citation factor among the authors is hardly decreasing and accounts for 70 per cent revealing the major disadvantage.

Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis.

IntroductionBedaquiline, pretomanid and linezolid (BPaL) is a new all oral, 6-month regimen comprised of bedaquiline, the new drug pretomanid and linezolid, endorsed by the WHO for use under operational research conditions in patients with extensively drug-resistant tuberculosis (XDR-TB). We quantified per-patient treatment costs and the 5-year budgetary impact of introducing BPaL in Indonesia, Kyrgyzstan and Nigeria.MethodsPer-patient treatment cost of BPaL regimen was compared head-to-head with the conventional XDR-TB treatment regimen for respective countries based on cost estimates primarily assessed using microcosting method and expected frequency of each TB service. The 5-year budget impact of gradual introduction of BPaL against the status quo was assessed using a Markov model that represented patient’s treatment management and outcome pathways.ResultsThe cost per patient completing treatment with BPaL was US$7142 in Indonesia, US$4782 in Kyrgyzstan and US$7152 in Nigeria – 57%, 78% and 68% lower than the conventional regimens in the respective countries. A gradual adoption of the BPaL regimen over 5 years would result in an 5-year average national TB service budget reduction of 17% (US$128 780) in XDR-TB treatment-related expenditure in Indonesia, 15% (US$700 247) in Kyrgyzstan and 32% (US$1 543 047) in Nigeria.ConclusionOur study demonstrates that the BPaL regimen can be highly cost-saving compared with the conventional regimens to treat patients with XDR-TB in high drug-resistant TB burden settings. This supports the rapid adoption of the BPaL regimen to address the significant programmatic and clinical challenges in managing patients with XDR-TB in high DR-TB burden countries.